Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management

详细信息    查看全文

• 作者：Jorge E. Cortes¹ ; ^{jcortes@mdanderson.org} ; Carlos A. Jimenez² ; Michael J. Mauro³ ; Alex Geyer⁴ ; Javier Pinilla-Ibarz⁵ ; B. Douglas Smith⁶
• 关键词：Adverse events ; Algorithms ; BCR-ABL1 ; Fluid retention ; Tyrosine kinase inhibitor
• 刊名：Clinical Lymphoma Myeloma and Leukemia
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：17
• 期：2
• 页码：78-82
• 全文大小：211 K
• 卷排序：17

文摘

Dasatinib has demonstrated durable clinical responses in patients, both as first-line and subsequent lines of therapy. Dasatinib use can result in pleural effusion in some patients, occurring any time during treatment and commonly characterized as mild to moderate in severity. Early identification of symptoms is essential in the proper management of pleural effusion. Prompt confirmation of diagnosis and management of pleural effusion can minimize morbidity and maximize the ability to preserve long-term clinical benefits with dasatinib. Here, we provide guidance on early identification and management of dasatinib-related pleural effusion.